The Venture Codex

Participated · Series A · Jan 2022

Juncell Therapeutics is focused on developing personalized TIL therapies for the treatment of solid tumors. The company says it has systematically optimized its cell culture processes and established an independent quality management system aligned with GMP specifications. Juncell reports achieving internationally advanced levels on metrics such as culture success rate, cell count, and cytotoxic activity. Clinically, its TIL therapy has shown strong efficacy in several patients with advanced solid tumors even without intensive lymphodepletion and IL-2 injection. The company also reports improved safety because patients have been treated in general wards. Juncell intends to focus on the TIL field and accelerate clinical development across multiple TIL pipelines, supported by recent financing.

Participated · Series C · Oct 2021

Founded in 2005, Lewei Pharma is a contract development and manufacturing organization (CDMO) focused on chemical process development and industrialization for innovative drugs. Its services cover process research, development, optimization, pilot and industrial production from preclinical stages through commercialization. The company has deployed R&D centers, production bases and an overseas business center and works with numerous global innovative-drug clients. Lewei handles hundreds of R&D and production project orders annually across therapeutic areas including oncology, central nervous system and metabolic diseases. Management highlights an experienced international service team and a competitive position in the small-molecule CDMO field. The company plans to use new funding to build a Cangzhou CDMO base, a Hefei new-drug R&D and GMP production base, and a Shanghai innovation accelerator laboratory.